Ozempic, other weight-loss drugs linked to rare but serious eye conditions
PTI
Melbourne, Aug 12 (The Conversation) Drugs such as Ozempic, Wegovy, and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.
Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels.
But two new studies published today show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss.
Here's what you need to know if you're taking or considering these medications.
What damage can occur? Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked. It's also called an 'eye stroke".
The exact cause of NAION remains unclear, and there are no current treatments available. People with diabetes are at increased risk of developing NAION.
Unlike other eye conditions that develop gradually, NAION causes a sudden, painless loss of vision. Patients typically notice the condition when they wake up and discover they've lost vision in one eye.
Vision tends to worsen over a couple of weeks and slowly stabilises. Recovery of vision is variable, but around 70 per cent of people do not experience improvement in their vision.
What has previous research shown? A previous study from 2024 found that participants prescribed semaglutide for diabetes were four times more likely to develop NAION. For those taking it for weight loss, the risk was almost eight times higher.
In June, the European Medicines Agency concluded NAION represented a 'very rare" side effect of semaglutide medications: a one in 10,000 chance. In a first for medicines regulators, the agency now requires product labels to include NAION as a documented risk.
However, the recent studies suggest the risks may be lower than we first thought.
In addition to NAION, there is also evidence to suggest GLP-1 drugs can worsen diabetic eye disease, also known as diabetic retinopathy. This occurs when high blood sugar levels damage the small blood vessels in the retina, which can lead to vision loss.
It may sound counterintuitive, but rapid blood sugar reductions can also destabilise the fragile blood vessels in the retina and lead to bleeding.
What do the new studies say? Two newly published studies investigated people with type 2 diabetes living in the United States over two years. The studies looked at the medical records of 159,000 to 185,000 people.
One study found that semaglutide or tirzepatide was associated with a more modest risk of developing NAION than previously thought. Of 159,000 people with type 2 diabetes who were taking these drugs, 35 people (0.04 per cent) developed NAION, compared with 19 patients (0.02 per cent) in the comparison group.
The researchers also found an increased risk of developing 'other optic nerve disorders". However, it's unclear what kind of optic nerve disorders this includes, as the medical record codes used didn't specify.
Counter to this, the second study did not find an increased risk of NAION among those taking GLP-1 drugs.
However, the researchers found a small increase in the number of people developing diabetic retinopathy in those prescribed GLP-1 drugs.
But overall, participants on GLP-1 drugs experienced fewer sight-threatening complications related to their diabetic retinopathy and required less invasive eye treatments compared to the group taking other diabetes medications.
Further studies are still needed to understand how GLP-1 drugs can lead to eye complications. A current, five-year clinical trial is studying the long-term effects of semaglutides and diabetic eye disease in 1,500 people, which should tell us more about the ocular risks in the future.
What does this mean for people taking GLP-1 drugs? NAION is a serious condition. But we need to strike a balance between these (and other) risks and the benefits of GLP-1 medications in diabetes care, obesity treatment, reducing heart attack risks and extending lives.
The key lies in informed decision-making and identifying different levels of risk.
People with multiple NAION risk factors – such as sleep apnoea, high blood pressure and diabetes – should undergo careful consideration with their treating doctor before starting these medications.
'Crowded" optic nerve heads are also a risk factor for NAION. This is an anatomical feature where blood vessels at the optic nerve head are tightly packed together. People with crowded optic nerve heads should also undergo careful consideration before starting GLP-1 medications.
Although NAION can strike without warning, regular comprehensive eye examinations with your optometrist or ophthalmologist still serve important purposes. They can detect other drug-related eye problems, including worsening diabetic retinopathy, and can identify patients with crowded optic nerve heads. It's also important to tell them if you are taking GLP-1 medications so they can keep a close watch on your eye health.
Emerging research also suggests that improving your heart health might help reduce the risks of developing NAION. This includes proper management of high blood pressure, diabetes and cholesterol – all conditions that compromise the small blood vessels feeding the optic nerve.
Studies also show that patients with heart conditions who better adhere to their medication prescriptions have lower risks of NAION than those who don't.
Doctors should discuss NAION risks during prescribing decisions and work with eye care providers to monitor regularly for diabetic eye disease. Patients need clear instructions to seek immediate medical attention for sudden vision loss and the need for regular eye examinations.
Aggressive treatment of sleep apnoea and other heart conditions may also help reduce NAION risks. But for now, there remains an ongoing need for more research to understand how GLP-1 medications can affect the eye. (The Conversation) SKS GRS GRS
(This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments
First Published:
August 12, 2025, 11:45 IST
News agency-feeds Ozempic, other weight-loss drugs linked to rare but serious eye conditions
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
(Bloomberg) -- If Novo Nordisk A/S's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.' It's not uncommon for drugmakers to study combinations of treatments when two seem to work for the same condition, in hope of boosting the benefit. Viehbacher said if Novo's study works, Biogen 'might' do trials looking at the two drugs in combination but cautioned the timeline might not make sense given Alzheimer's studies take years to complete. Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30% of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39% tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. More stories like this are available on
India Today
4 hours ago
- India Today
From Rs 30,000 to Rs 3,000, India's weight-loss game is changing. What's the catch?
India is on the brink of a weight-loss revolution. What has long been a luxury reserved for the ultra-rich is now on the cusp of becoming mainstream. With anti-obesity drugs like semaglutide set to drop in price from a staggering Rs 30,000 to just Rs 3,000 per month, millions of Indians battling weight issues could finally gain access to life-changing pharmaceutical giants gear up to flood the market with affordable generics, 2026 is expected to mark not just the arrival of next-gen weight-loss medication—but the beginning of a nationwide health is this transformation entirely welcome? And are we prepared for what it brings? First let's understand, why now?Globally, GLP 1 drugs like Ozempic and Wegovy have already helped nearly 20 million people lose weight since 2021. But in India? Access has been painfully slow and painfully expensive. Until now. The core ingredient in these blockbuster drugs, semaglutide, is going off patent in 2026 not just in India but in over 80 countries including Canada, China, Brazil, and Saudi that happens, prices are expected to fall hard—by as much as 85 to 90 percent. That means what once cost Rs 20,000 to 30,000 a month could soon be available for as little as Rs 2,500 to Rs 4,000. For the average Indian earning around Rs 17,000 a month, that's a massive shift from completely out of reach to will be a fundamental shift in who gets to access obesity care. We're talking about taking weight-loss drugs from elite clinics in metros and putting them in the hands of everyday Indians. With nearly 33 percent of Indian adults struggling with obesity, this could have a massive public health impact. But with mass access comes a set of new SOUND CAUTION: WILL THIS ACCELERATE MISUSE?While the promise of affordable treatment is exciting, doctors are urging caution.'Undoubtedly the reduction in cost will allow access to a much larger segment of the Indian population, the drugs will not be elite anymore. Whenever prices go down, it always helps our patients. I assume the quality checks will be maintained as generics enter the challenge of course is, that misuse will become easier. Misuse might already be happening, and this could further increase. But overall, I think the benefits outweigh the challenges, I am quite optimistic about this move,' says Dr. Ambrish Mithal, India's leading endocrinologist and author of "The weight-loss revolution."To handle the misuse, countries like Portugal have given only doctors with approved specialities, permits to prescribe these drugs as a way of controlling the misuse. Something that doctors in India are now and when the drugs will become more affordable it will clear impact entire spectrum of more than 200 conditions which are impacted with people living with obesity. The cosmetic use and misuse of label need to be contained because these drugs have compelling data on complications and co morbidity and must be given under expert supervision,' warns Padma Shri Dr Shashank Joshi, who has been at the forefront of diabetes and obesity care in there is a genuine sounding of caution, there is also the flip side to the generic race for weight-loss patents expiring, the doors are wide open for Indian pharma players to jump in and they're wasting no time. Over 10 Indian companies have already filed for clinical trials, mostly for oral versions of semaglutide (no injections necessary).Add to that the competition from Chinese manufacturers, and what you get is a perfect storm of falling prices. Experts predict costs could plunge by up to 70 percent even before 2026, as generic versions hit the shelves and reshape the this isn't just a drug story. The ripple effects across the healthcare ecosystem could be enormous: Insurers may begin covering weight-loss therapies, Hospitals may roll out dedicated obesity programs, Startups are already building subscription-based models that combine medication, coaching, and lifestyle trackingadvertisementIt's not just about shrinking waistlines—it's about reimagining public health.A CLEARER TIMELINE: WHAT TO EXPECT AND WHENHere's how the semaglutide story is expected to play out in India:Late 2025: Branded semaglutide drugs become legally available in India through formal pharma 2026: Patent expiration triggers launch of the first Indian-made generics—both injectable and to late 2026: Prices drop significantly (up to 85 to 90 percent), demand spikes, and mass availability 2027: Generic semaglutide becomes a first line treatment for obesity across urban and semi urban conclusion, what was once a Rs 30,000-a-month treatment is set to drop to Rs 3,000 or less. That's a game-changer—not just for individuals, but for India's public health system.2025 has already seen the early entry of next-gen weight-loss drugs into the Indian market. 2026 will be the year they go if we want this revolution to truly succeed, we need more than cheap drugs. We need education, regulation, and ethical if we're not careful, India could end up facing the same problems the West is already struggling with—from overuse and side effects to social media-fuelled that's not the kind of health transformation anyone wants.- EndsMust Watch
Indian Express
7 hours ago
- Indian Express
Can blockbuster weight loss drugs affect your eyes? Here's what new studies have found
Can the new class of diabetes and obesity medicines, which are being hailed as blockbuster weight loss drugs, affect your eyesight? Two recent studies, published in JAMA Network Open, have now confirmed the association of semaglutide and tirzepatide with an increased risk of certain eye conditions. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue, which mimics the effects of the natural GLP-1 hormone in the body, regulating blood sugar levels and appetite. It is used to treat type 2 diabetes and, in higher doses, for weight management. Tirzepatide mimics the effect of both GLP1 and GIP, a hormone that stimulates insulin release from the pancreas and helps regulate blood sugar and weight. Researchers focussed on how these drugs were linked to diabetic retinopathy (a condition where high blood sugar levels damage the tiny blood vessels in the retina and can cause blindness) and NAION (Non-arteritic Anterior Ischemic Optic Neuropathy, a condition where blood flow to the nerve reduces, leading to sudden, painless vision loss). The first study looked at data of people with Type 2 diabetes on any GLP-1 medicine (including older molecules such as dulaglutide and liraglutide) and compared it with people on other diabetes medications. During the two-year follow-up, the researchers found that the risk of both diabetic retinopathy and NAION was higher in those taking GLP-1 medicines. The good news, however, was that these medicines were linked to a lower all-cause blindness and lower rate of the sight-threatening complications of diabetic retinopathy such as bleeding in the space between the lens and retina of the eye or a severe form of eye condition where blood vessels grow abnormally in the eye. In patients with diabetic retinopathy, the use of the medicine did not lead to progression to advanced stages. The researchers also noted a reduced need for medical, surgical, or laser-based treatments for these conditions. The second study compared the patients who were on the strongest GLP-1 medicines like semaglutide and tirzepatide with those on any other diabetes medicines including insulin, metformin, or even the older GLP-1 medicines. During the two-year follow-up period, the researchers noted a slight increase in cases of NAION and other optic nerve disorders. The studies were conducted to verify concerns about diabetic retinopathy that were raised nearly a decade ago during the initial trials of semaglutide. This prompted heightened scrutiny for eye diseases and led to the exclusion of high-risk individuals from further trials. More recently, a study from a single centre showed an increase in incidence of NAION in patients on semaglutide. This prompted further studies to understand the impact of these medicines on the eye. The European Medicines Agency now says that NAION is an extremely rare adverse reaction that may affect one in 10,000 people who are on semaglutide. Similar studies would now be needed for tirzepatide as well. Should you continue taking your prescription? Yes. The researchers say while there is some increased risk of these eye conditions, the GLP-1 medicines themselves have been transformative when it comes to diabetes and obesity management. There is also evidence coming in to show the benefit of these medicines on heart, kidney, and liver conditions linked to diabetes and obesity. Researchers say patients should be informed about the risk of eye conditions when they are prescribed the drugs. They suggest that people who already have diabetic retinopathy should undergo close ophthalmic monitoring when the drugs are initiated or when the doses are increased. They recommend that the medicines be gradually upgraded to avoid sudden swings in blood glucose levels that can affect the eye. For this purpose, they suggest a collaboration between diabetologists and eye specialists. The researchers have further suggested that parameters for eye safety be made a part of all future GLP-1 medicine trials.
